Objectives: Research on pain severity and health outcomes, especially healthrelated quality of life (HRQoL), is often done in a specific disease area examining specific domains within HRQoL. Although important, this research says very little about the relationship between general pain severity (across conditions) and domains of HRQoL. The purpose of this study was to investigate this relationship using a large sample of EU patients diagnosed with pain. MethOds: Data came from the 2013 EU National Health and Wellness Survey (NHWS; n= 62,000). The NHWS is a crosssectional general health survey assessed yearly in the 5 EU (UK, France, Spain, Italy, and Germany). Those individuals who reported a diagnosis of one or more pain types were the focal subsample of this analysis (n= 14,459). Patients' HRQoL was assessed via the SF-36 and their pain in the past week was measured on an 11 point selfreport scale from 0 "no pain" to 10 "pain as bad as you can imagine". Results: Initial descriptive results showed that there were large mean differences in SF-36 domain scores for those with a diagnosis of pain vs. those without. The largest differences were observed for the bodily pain (M= 40.91 vs. 51.88, p< .001, d= 1.06), general health (M= 42.89 vs. 50.68, p< .001, d= .80), and role emotional (M= 43.93 vs. 51.04, p< .001, d= .75) scales. With regard to pain severity in the past week, the strongest correlations were observed for the bodily pain (r= -.63, p< .001) and role physical (r= -.46, p< .001) scales. After controlling covariates, these associations still held for both the bodily pain (β = -.59, p< .001) and role physical scales (β = -.45, p< .001). The nature of the association between severity (e.g., linear, quadratic) was also examined for each SF-domain score. cOnclusiOns: Results suggest that the association between pain severity and HRQoL is nuanced and that pain affects different domains of HRQoL to varying degrees.
Objectives: Children with GHD can experience physical symptoms and diseaserelated impacts on functioning and well-being. However, no GHD-specific measures exist to assess these impacts. The purpose of this qualitative study was to collect data to support the conceptual validity of a new measure, with a patient-reported outcome (PRO) version for older children and an observer-reported outcome (ObsRO) version for parents/guardians. MethOds: Focus groups and interviews were conducted with 39 children (aged 8-12) with GHD, 31 parents of children with GHD (aged 4-12) and eight clinical experts in three countries (Germany, UK, US). Interviews were analysed and coded using adapted grounded theory to determine overarching themes and concepts. Based on the analysis, a conceptual model of the impact of GHD was developed and items for both versions generated and then cognitively debriefed. Results: Qualitative analysis found the saturation of concepts was reached with four domains of impact: Symptoms, Physical, Social, and Emotional. Sub-concepts included appetite (48%), strength (42%) and energy level (38%) for Symptoms; limitations in physical performance (58%) and reaching (44%) for Physical; mistaken for younger (58%) and teasing (41%) for Social; and worry (55%) and self-confidence (41%) for Emotional. Emotional impacts were often related to others' perception or treatment of the child as younger. Children and parents reported consistent symptoms/impacts, although severity of impacts sometimes varied. Impacts were moderated by factors including velocity of physical growth and age at treatment initiation. All versions were cognitively debriefed in a new sample (N= 26: 13 children, 13 parents) and, based on findings, it was determined that the PRO version was appropriate for children aged 9-12. A 32-item TRIM-CGHD (PRO and ObsRO versions) was finalized. cOnclusiOns: The conceptual validity of both versions of the TRIM-CGHD is supported by these qualitative findings and the measure is now ready for psychometric validation.
PSY91 imPAct of weight loSS on PAtient-rePorted outcomeS in the ScAle oBeSitY And PrediABeteS triAl of lirAglutide 3.0 mg AS Adjunct to A diet And exerciSe (d&e) ProgrAmme
Kolotkin RL 1 , Meincke HJ 2 , Manning LS 2 , Bjørner JB 3 1 Quality of Life Consulting, Durham, NJ, USA, 2 Novo Nordisk A/S, Søborg, Denmark, 3 Optum, Lincoln, RI, USA Objectives: To explore impact of weight loss on patient-reported outcomes in individuals without type 2 diabetes, but with obesity (BMI ≥ 30 kg/m2) or overweight (BMI 27.0-29.9 kg/m2) with ≥ one comorbidity. Patients were randomised 2:1 to once-daily liraglutide 3.0 mg (n= 2487) or placebo (n= 1244) as adjunct to D&E. MethOds: Impact of Weight on Quality of Life-Lite (IWQOL-Lite) and Short-Form 36 v2 (SF-36) questionnaires were administered in countries with validated translations (approx. 82% of individuals). Data are reported as estimated change at end-of-trial, derived using ANCOVA with LOCF; increased scores signify improvement. This post hoc analysis was based on categorical weight change from baseline. Results are reported for liraglutide 3.0 mg, placebo respectively, as follows: A = weight gain; B = weight loss 0−4.9%; C = weight loss 5−9.9%; D = weight loss 10−14.9%; E = weight loss ≥ 15%. Results: For individuals in the trial overall, greater proportions treated with liraglutide 3.0 mg versus placebo were in the higher weight loss categories: A 7.4%, 34.3%; B 29.5%, 38.6%; C 30.1%, 16.6%; D 18.7%, 7.0%; and E 14.4%, 3.5%. For those completing the IWQOL-Lite (n= 1890 liraglutide 3.0 mg, n= 886 placebo) and SF-36 (n= 1689, n= 796 respectively), similar profiles were observed, with liraglutide 3.0 mg achieving higher categorical weight loss than placebo. Changes in IWQOL-Lite total score were lowest in the weight Objectives: To cluster health status among adults with hemophilia by applying the hidden Markov model (HMM) to account for longitudinal changes in quality of life scores and to derive utility weights for each cluster. MethOds: Data were obtained from the Hemophilia Utilization Group Studies (HUGS), a prospective, multi-center observational study conducted from 2005 to 2013. Demographic and clinical characteristics, bleeding frequency and health-related quality of life (SF-12) at initial interview and 3-month follow-up visits for 2 years were collected. This analysis included data for 211 adults with hemophilia A or B with at least two observations. The HMM was adapted to generate the clusters and to fit the observation sequences, which consisted of SF-12 physical component scores (PCS) .6] from cluster 1 to cluster 4, respectively. Utility weights for each cluster were 0.91±0.05, 0.75±0.11, 0.65±0.11 and 0.55±0.08, respectively. At baseline, 49 (23%) adults were classified in cluster 1, 63 (30%) in cluster 2, 67 (32%) in cluster 3 and 32 (15%) in cluster 4. Being in a worse health cluster was significantly associated with unemployment, low household income, having severe hemophilia and higher BMI. The mean bleeding frequencies during a 3-month period were 1.54±2.62, 3.01±4.91, 3.80±4.09 and 4.83±5.69 among those who were assigned to cluster 1 to 4, respectively (p< 0.0001). cOnclusiOns: Health status in hemophilia can be described by four mutually exclusive and clinically relevant clusters, which provide patients' value of health outcomes for future economic analyses.
PSY87 oPioidS Switch in chronic PAin: imPAct ASSeSSment uSing electronic heAlth recordS
Ussai S 1 , Petelin R 2 1 Young Against Pain (YAP) Group, Parma, Italy, 2 Laboratorio Salute, Naples, Italy Objectives: Patients with chronic pain frequently require strong opioids for pain relief. While most patients achieve adequate analgesia, a significant minority either suffers intolerable side effects and/or inadequate pain relief leading to opioid switching. The lack of a National Pain Care Registry does not permit a successful investigation in this topic. MethOds: Study population included all outpatients with chronic pain voluntarily participating in a cloud based medical surveillance system. Each patient was anonymously linked through an alphanumeric code to all opioid prescription (Anatomical Therapeutic Chemical code N02A) in a 18-month period. Chronic use was defined as taking the medication for more than 90 consecutive days. The prevalence of chronic use was calculated as the ratio between the number of subjects taking the medications more than 90 days consecutively and the total number of subjects with at least one opioid prescription. This study aims to assess (a) the pattern of opioid chronic use, (b) switching of active substance. Results: Out of about 2,400 occasional users of opioids analgesics, 41 (1.7%) were chronic users. Women represented 70.7% of chronic users (N= 29). A total of 37 (90.2%) chronic users switched active substance at least once during the study period. cOnclusiOns: In this outpatient population, the majority of chronic users switched active substance at least once during the study period. These results may suggest that poor pain control or/and unintended side effects could be a leading cause of active substance switching. Otherwise, for patients with inadequate pain relief and intolerable opioid-related toxicity/adverse effects, a switch to an alternative opioid may be the only option for symptomatic relief. However, the evidence for the effectiveness of opioid switching does not appear to be established.
PSY88 vAlidAtion of A new hemoPhiliA-SPecific Burden ScAle for cAregiverS of children with hemoPhiliA in the uS -the hemoPhiliA ASSociAted cAregiver Burden ScAle (hemocABtm)
von Mackensen S 1 , Wisniewski T 2 , Urgo J 3 , Boggio L 3 1 University Medical Centre Hamburg, IL, USA, 2 NOVO Nordisk, Plainsboro, NJ, USA, 3 RUSH University Medical Centre, Chicago, IL, USA Objectives: Hemophilia is a hereditary bleeding disorder characterized by spontaneous and traumatic bleeding requiring regular or episodic infusion of clotting factor. Taking care of a child with hemophilia (CWH) is burdensome for caregivers. For the assessment of caregivers' burden standardized questionnaires are needed. We developed the "Hemophilia associated Caregiver Burden Scale" (HEMOCABTM). MethOds: Questionnaire development included: 1) item generation (two semi-structured focus groups with 11 caregivers, evaluation of existing caregiver burden scales for relevance by 16 HCPs); 2) feasibility testing (cognitive interviews with 12 caregivers) and 3) pilot-testing in caregivers of CWH with and without inhibitors < 22 years old (psychometric analysis of HEMOCABTM). Results: Item generation resulted in a revised questionnaire containing 108 questions pertaining to 13 domains. Forty caregivers (75% mothers) completed the HEMOCABTM (mean age of 39.32±8.9). The majority of CWH had hemophilia A (95%), inhibitors (15%), were severely affected by hemophilia (77.5%), and had 4.83±8.9 bleeds in the last year. Caregivers reported spending 8.69±7.7 hours per month on infusion and 3.84±6.7 hours per month travelling to the hemophilia centre. Psychometric testing of the HEMOCABTM showed good values for reliability (Cronbach's alpha of TOTAL score: α = .97; 'FREQUENCY': α = .95 and 'BURDEN': α = .92) and validity (convergent, known groups). HEMOCABTM correlated highly with the IOF (r= -.867 for total score) and revealed significant differences among caregivers of CWH with inhibitors vs. without in all domains of HEMOCABTM except for 'school'. Caregivers reported highest burden in the domains 'perception of child', 'emotional stress' and 'financial burden'. cOnclusiOns: Based on item and scale analysis 49 items were deleted and the final HEMOCABTM consists of 59 items. HEMOCABTM is the first hemophiliaspecific instrument for the assessment of caregiver burden with good psychometric characteristics in terms of reliability and validity. In a next step we will examine the sensitivity to change of the revised HEMOCABTM.
